Last reviewed · How we verify
Atazanavir/ritonavir monotherapy
Atazanavir/ritonavir monotherapy is a HIV protease inhibitor Small molecule drug developed by IRCCS San Raffaele. It is currently in Phase 3 development for HIV-1 infection (monotherapy maintenance in virologically suppressed patients). Also known as: ATV/r monotherapy.
Atazanavir/ritonavir inhibits HIV protease to prevent viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition.
Atazanavir/ritonavir inhibits HIV protease to prevent viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition. Used for HIV-1 infection (monotherapy maintenance in virologically suppressed patients).
At a glance
| Generic name | Atazanavir/ritonavir monotherapy |
|---|---|
| Also known as | ATV/r monotherapy |
| Sponsor | IRCCS San Raffaele |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Atazanavir is an HIV protease inhibitor that blocks the viral protease enzyme required for processing HIV polyproteins into functional viral proteins, thereby preventing viral maturation and replication. Ritonavir is a potent CYP3A4 inhibitor used at sub-therapeutic doses to increase atazanavir plasma concentrations, allowing for lower atazanavir dosing and improved pharmacokinetics. This combination is being evaluated as monotherapy to simplify HIV treatment regimens.
Approved indications
- HIV-1 infection (monotherapy maintenance in virologically suppressed patients)
Common side effects
- Hyperbilirubinemia
- Nausea
- Diarrhea
- Headache
- Rash
- Abdominal pain
Key clinical trials
- Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression (PHASE3)
- Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir/ritonavir monotherapy CI brief — competitive landscape report
- Atazanavir/ritonavir monotherapy updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI
Frequently asked questions about Atazanavir/ritonavir monotherapy
What is Atazanavir/ritonavir monotherapy?
How does Atazanavir/ritonavir monotherapy work?
What is Atazanavir/ritonavir monotherapy used for?
Who makes Atazanavir/ritonavir monotherapy?
Is Atazanavir/ritonavir monotherapy also known as anything else?
What drug class is Atazanavir/ritonavir monotherapy in?
What development phase is Atazanavir/ritonavir monotherapy in?
What are the side effects of Atazanavir/ritonavir monotherapy?
What does Atazanavir/ritonavir monotherapy target?
Related
- Drug class: All HIV protease inhibitor drugs
- Target: All drugs targeting HIV protease
- Manufacturer: IRCCS San Raffaele — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection (monotherapy maintenance in virologically suppressed patients)
- Also known as: ATV/r monotherapy
- Compare: Atazanavir/ritonavir monotherapy vs similar drugs
- Pricing: Atazanavir/ritonavir monotherapy cost, discount & access